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9:30 • Intsractlon of Antagonists With the Platelet 
GPllb/tlla: Charactsrlsatlon of Two Monoclonal 
Antibodies that Detsct Orug Binding 
M J. Ouinn, D,M, Cox, P Thoroux, DJ, Fitzgerald. Royal Coflege of 
Surg~xt$ in Ire~nd, Oublin, lmlart# and th~ Montr~it Heart Instffute, 
Canada 
B~!c~g~mo~. 7E3 and SYnthetic ant~ge~tsts dtflemn1~lly dtspla¢~ two mono- 
clonal anttbod~ from GPIIb/ll!a, M~t  and Mab~3. Hem we fuflher chafed.- 
tense the in ter~o~ be~ the~ antibed~es and GP!l~l!la antagonists 
Methoo~- FlOw o/tom~tr~ w~a g_sed to detect binding o! MalP1 and Mab~3 
on platelels~ ~H.SCS?t0t (~H-SC), a GPIIb.qlta antagonist, was used as a 
tiga~ to~ ~re,~l~o~ assays, 
Results: ~1 was d~4~aced by ~3 (!C50 = 600 ngtmt), whereas sym 
there GPllb.qtta aofago~nists had no etfect, Mab-t d~s~aced ~H-SC and 
prevented platetet aggreg~3bon, suggesting that they interact w~th the t~t'~lin o 
pocket, Suq~smgty, 7E3 ~ no effect on ~H-SC binding, Mab-3 was not 
~ k ~  by ~3,  sugges~ng mat it recogn~ an ep,tope remote horn the 
hgand recognition pocket. ~ 3  Was ~splated. I'~:~,~ver, by several sys- 
thetis GP!lb/tlia anfago~sts (!ntegrekn IC50 = 200 ngh~l). In cordrast, Ma~3 
d~t not Prevent but rather enhanced the t~ed*ng o! ~H.SC. These data sug- 
gest that Mab.3 and GPIIb/llla anlagOn~sts interact wtth (hfferent ep~ropes 
The d~sl~acement of Mab-3 by GPIII~IIla antagonists suggests that these 
agents. =n contrast to ~3,  reduce a co~ormat~onal change in the receptor 
w~th ross of the Mab-3 ep~tope. 
Conch '  Bind.rag of Man-1 and Mab-3 to ptatetets provzdes a novel 
al~math to folte,,~ng I~nG~recepto~ mtera¢1,xm5 dunng the admmLstration 
of GPttb/llta antagonists in v~o. 
9:45 
[ -8"7~ Compatrison of Platelet Agg~n Response and 
Receptor Occupancy of RPR 109891 Administered 
Intravenously in Patients W'dh Recent Acute 
corotm~ Syndromes (~m~ SA) 
L. J~nnmgs. R WLse. K. Ramsay. M. JacoskL J.-F Tamby. S. May, 
M. Wh(te, S. Cholera. C. ~ .  M To(h3. J. Rush. R. G~ugh~no. 
~tsd) ,  ot TN. t~r~phP3. TN. Rhor~ Pout~nc Ro~r. Coltegewlte. PA. and/ 
Bngttam and Women's Hosp~l. Bosto~ MA USA 
Background: RPR 109891 Ls a platelet fibnnogen receptor ar~ago~st that 
=s avatlab~e as both an oral and an IV fom~ulabon. TIMI 15A ~ a Phase tl, 
ra~J  trial of IV RPR 109891 for the treatment ot acute o0ror~ry 
sy~romes 
Methods: Of f~-e treatment re~mens of a bolus followed by an ~n~on 
rate. three were irNest~gated: 30 ~+~kg/3 mm and 0.4 .g,~kg~mm: 45 ~=g~kg~3 
mm and 0 6 ~,g,'kg,'mm; and 60 ~=g/kg~3 mm and 0.8 ~,g/kg/mm An ob~e~l~ve 
was to evaluate mhtb~tmn of p;atelet aggregation (IPA) using ADP and TRAP. 
The extent of receptor occupancy (Re) was also determined by the unique 
b~ndmg prop~rt~-~s of the D3 mAb. D3 bnd=n 9 to GPtlb-II|a m~as,.~es the 
pement of total GPllb-Illa receptors w~th bound drug. Both PA and Re 
were earned out at immedmtely before RPR 109891 was admmmtered, at 
bmepoints after drug imtiation, pnor to drug olscontinuation, and at 2-4 hr 
and 8.-24 hr after discontinuation 
Results: Re data showed that the two lowest doses had equtvalent Re; 
67% el the patients had a Re of .90%; however. 85°;0 of the patients had 
- 90% Re at the highest dose. IPA data gave similar resuRs; the intermediate 
dose resulted in 50% of the patients wlth >95% IPA: the highest dose resulted 
in at least 85% of the patients w~th :-95% IPA. IPA w=th TRAP indicated that 
even though Re was .gO%. TRAP-reduced surface expression of internal 
GPIIb-Illa reduced the IPA at steady state to 81%. Thus. spare receptors 
may play a role in efficacy of blockade. 
Conc/us,~oos: Both IPA and Re are tLSeIul in evaluating the effechveness 
el RPR 109891 tn GPIIb-Illa receptor btockaffe. The doses chosen were 
within the desired range for initial evaluation. 
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Electrical Cardiovetltlon of Atfla! Fibrillation: 
ROIults From the ACUTE Regll W 
RA, Gnmm, D,A, Agler, S.E. Va~hn, M Than~larasan, M K Chung, 
G .qcaha, RD. Murray, J [3 Thomas, AL  Klein, For the ACUTE 
mveslgators. The CI¢,~eland Clin¢, Cleveland. OhKX USA 
Backg/ouncl: Electrlca~ cardiovefSK~n (DCC) el atflat fibnllat~ (AFI 0s as- 
sociated Wt~ an embol,c eveof rate el "~2%. TEE.guK~ed DCC has been 
employed as an attematwo to ¢onventK:m, al ant¢oagutatlon (ACi mana,~eP 
ment as a means of minimizing th!s event rate While s(mpi~png the AC 
regimen, However pre~ous SludieS of th*s method have been hm*ted by 
ratatwely small sample sTzes 
Mettmo~: We stu~ed 417 consecutwe pts who underwent a TEE pnor to 
a Planned DCC of AF at the Cleveland Ctinm ~om Jan 'gt-Dec '96 Pattents 
were toltewed for Stroke for 4 wke to (~terr~ne the e~cacy of thts strategy 
ReSults: Mean age 67 ~- t2 ym, 73% mate and mean duratton of AF was 
t 79 oays Eighty six percent were am~coagutated at the time of DCC for a 
me.an duratmn ot only 5 clays pnor Left atrial (LA) diameter was 5 +~ 1 cm 
and mean LV elect:on fraction was 44 ± 16%. Atnat thremts were detected 
in 28 pts (7%) ,n whom DCC was postponed. DCC was perfon~m m 388 pts 
of wt~ch 364 were successfully cotweffed to sinus rhythm. Although mere 
were 2 deaff~ m the pts tm~ergomg OCC wnt~n the 4 wk follow-up period 
there were no car~oerd0ofic events. 
Conclusion TEE-GuYEd AC management of pts w~th AF unck~rgomg 
DCC ~s safe and effective and has a s,gmhcantty tower emb~ie event rate 
comoareO wd'n published evenl rates using cortvent~onat AC management 
8:45 
~2-~ Prevalence of Atrial Thrombi in Patients Undergoing 
Electrical Cardioversion - Results From the ACUTE 
Remarry 
M. Than~arasan, R.A Gnmm. M.J. Garma, S.E Vaughn, DA. Agler, 
& Morehead, J_A. Odabash~an LA. C.ardon, S.C. Enar, A.L Klein. The 
Clave~ariel Chn~c Foundat~n. Cleveland, OH, USA 
Background: Atnal thrombt and resultant card*oemCotic events produce s~g- 
ndicant modo~dtty in pts. wdh atnal fibrillation (AF) We sought to ~denhty 
the prevalence and clinical charactenst=cs of pts. w~th atn~l thromb= ~n a 
iarge cohort of pts referred for trartsesophageal (TEE) guided cardtoverslon 
~DCC) 
Mall"rods: We performed TEE, as part of the ACUTE regml~y, in 330 
pts. prior to DCC. Of the~e. 308 pts underwent DCC, and in 22 (7%) the 
procedure was aborted due to the presence of atnal thrombi. 
Resull's. The mean age m those w~th thrombus was G3 ysaPs (16 were 
male). Twenty-one pahent~ had left atnal (LA) thromb~ (3 pts ~th thrombus m 
LA 13<~3~, 16 w~th LA appendage (LAA) thromDL and 2 wtth thr0mbt n befit LA 
and LAA) and one pahent had a nght atnal thrOmbus. All pts. wtth thrombus 
had 5Oor~aneous ectlo co.rest, w~th 17 of the 22 ha.~ng severe smoke. All 
were on a~coagulation at the time of their TEE. Duration of AF ranged from 
5-1500 days. w~th 5 pts h~n~ng had A= for one week or less. Mean ejection 
fraction was 34%, and mean LV mass was 323 grams, The LA mean area 
was '25 crn ~ and mean LA dimension was 4.8 ~ by transthoraoc eChO 
LAA area averaged 74 ~'n ~' . ~th peak LAP, emptying velooty averaging 26 
c.w~s.ec 
Conclusion: In the ACUTE regTstry Of pts referred for cardtoversiOnr 
93% were free ot atnal thrombus. Those w~th LA thr0mbus tended to have 
LV dysfunction w~th LA enlargement, w=th low LAA emptying velooties and 
smok~. 
9:00 
-~ Left Atrial Stunning in Patients With Appendage 
Paroxysmal Atrial Fibrillation: A Transesophageal 
Echocardiogtaphy Study 
H. Kate. N. Tanaka. K. Watanabe. K. Hashimoto. Y. KubO, H. Muraktta. 
N. Maekawa. T. Oholshi, M. Yamamoto. Fukui Kosei Hospital. Fugue. Ja/3an 
Background: Recent echocardiographic studies have suggested that atnal 
stunning is frequently observed immediately after electrical cardioversion in 
chronic atnal fibrillation. We assessed the prolonged dysfunction of the le~t 
atnat appendage (LAP,) caused by paroxysmal atnal fibnltation (PAF). 
